Ancillary therapy

BEHAVIORAL4 trials

Sponsors

Orexigen Therapeutics, Inc

Conditions

Diabetes Mellitus, Type 2Nicotine DependenceObesityOverweight

Phase 2

A Study of Naltrexone SR/ Bupropion SR in Overweight and Obese Subjects Who Are Nicotine-Dependent

CompletedNCT00563563

Orexigen Therapeutics, IncNicotine Dependence, Obesity, Overweight

Start: 2007-10-31End: 2008-09-30Updated: 2012-11-02

Phase 3

A Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Subjects With Type 2 Diabetes

CompletedNCT00474630

Orexigen Therapeutics, IncDiabetes Mellitus, Type 2, Obesity, Overweight

Start: 2007-05-31End: 2009-06-30Updated: 2014-11-21

A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects

CompletedNCT00532779

Orexigen Therapeutics, IncObesity, Overweight

Start: 2007-10-31End: 2009-05-31Updated: 2014-11-21

A Safety and Efficacy Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects

CompletedNCT00567255

Orexigen Therapeutics, IncObesity, Overweight

Start: 2007-12-31End: 2009-06-30Updated: 2014-11-21

Related Papers

How many unpublished studies? ClinicalTrials.gov (n = 2614 studies): diabetes | Closed Studies | Interventional Studies | Phase 3, 4 | Search Date: Oct 27, 2014

Figshare2014-01-01

Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

2010-07-29622 citations